Targeting the Unfolded Protein Response: Market Intelligence, Clinical Progress, and High-Purity Kinase Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HsPEK (PERK/EIF2AK3) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Kinase Domain) | HsPEK Kinase Domain Recombinant Protein, >95% purity, Endotoxin <1EU/ug, Sequence Verified, ATP-binding site integrity confirmed, HEK293 expressed (native folding). | View HsPEK Products |
| Antigen (Mutant Panel) | HsPEK Resistance Mutants (Gatekeeper variants), Theoretical MW verified, High purity for selectivity screening. | View HsPEK Products |
| Gene Delivery | HsPEK Promise-ORF / Lentivirus, Full-length PERK for stable ER membrane expression. | View HsPEK Products |
| Benchmark Ab | Anti-HsPEK Benchmark Antibody, Recombinant positive control for Western/Flow. | View HsPEK Products |
| Validator | HsPEK siRNA Set, For knockdown verification and assay specificity. | View HsPEK Products |
| Related Target: IRE1α | ERN1 (IRE1α), Parallel UPR stress sensor pathway. | View IRE1α Products |
| Related Target: GCN2 | EIF2AK4 (GCN2), Paralog kinase for selectivity counter-screening. | View GCN2 Products |
| Related Target: ATF6 | ATF6, Parallel ER stress sensor. | View ATF6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Kinase Activity in vitro | HEK293 expressed (native folding), >95% purity, Endotoxin <1EU/ug. |
| Kinase Selectivity (vs GCN2, PKR, HRI) | Ortholog kinase panel available with >95% purity, Sequence verified ATP-binding domains. |
| Resistance Mutation Profiling | Gatekeeper and Activation Loop mutants strictly verified by mass spec; High purity for selectivity screening. |
| Cellular UPR Assay Development | HEK293 expressed lentivirus for stable PERK overexpression; Native glycosylation preserved. |
| Lack of Controls | Benchmark Antibodies included for standardized assays. |
| False Positives in Cell Assays | Validated siRNA included for target engagement confirmation. |
Live HsPEK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HsPEK (PERK) therapeutics is intensifying, with major players shifting from pan-kinase inhibitors to highly selective allosteric modulators. As first-generation ATP-competitive therapies reach Phase I/II for pancreatic cancer and glioblastoma (players: GSK, Ideaya, Amgen, Pfizer, Biogen), the next wave of R&D is targeting blood-brain barrier permeable compounds for neurodegenerative diseases including ALS and Alzheimer's (Denali Therapeutics, Calico, AstraZeneca). As an integral component of the Unfolded Protein Response (UPR), HsPEK plays a crucial role in tumor survival under hypoxia and ER stress. Future trends indicate a shift towards combination therapies with immune checkpoint inhibitors or proteasome inhibitors, and novel applications in neurodegeneration. The emergence of PROTAC degraders and allosteric modulators broadens the therapeutic landscape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Oncology) | GSK, Ideaya, Amgen, Pfizer, Biogen | Solid Tumors, Melanoma, Glioblastoma | Selectivity Assay (need high-purity kinase domain and ortholog panels) |
| Small Molecule (CNS) | Denali Therapeutics, Calico, AstraZeneca | ALS, Alzheimer's | Target Engagement (need pure WT proteins and cell-based UPR reporter assays) |
| PROTAC | Emerging Biotech | Refractory Cancers | Degradation Assays (need specific Ab controls) |
| Allosteric Modulator | Various Biotech | ER Stress Diseases | Conformation-specific binding (need mutant panel) |
Key Mutations and Functional Domains
HsPEK (EIF2AK3) encodes a protein kinase domain (UniProt Q9NZJ5). Key reported mutations include:
- WRS variant (VAR_089927)
- Single nucleotide polymorphism rs867529 (VAR_011409)
- Single nucleotide polymorphism rs13045 (VAR_011410) These mutations may affect kinase activity and drug resistance profiles, making mutant protein panels essential for selectivity screening.